mrna

Moderna and Merck announced positive Phase 3 results for intismeran autogene, an mRNA-based individualized neoantigen therapy, in adjuvant treatment for melanoma.

An experimental mRNA-based cancer vaccine has successfully prevented melanoma from returning in a late-stage study, marking the first validation of decades of custom-treatment research.

Moderna's mRNA flu vaccine mFLUSIVA received FDA approval for adults over 50, marking the first mRNA-based flu shot. However, uncertainty remains due to the CDC advisory panel being defunct amid litigation, affecting coverage recommendations.

Moderna announced FDA approval of mFLUSIVA (mRNA-1010), a seasonal influenza vaccine for adults 50 and older, following unanimous advisory committee recommendations.